Patents by Inventor James John Eshelby

James John Eshelby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6962923
    Abstract: Compounds of formulae (IA) and (IB): wherein R1, R2, R3, Ar1 and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: November 8, 2005
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Darren John Schulz
  • Patent number: 6777412
    Abstract: The invention provides fungicidal compounds of formula (I) or stereoisomers thereof: wherein X is CH2O; A is hydrogen; E is hydrogen; q is 1; any two of K, L and M are nitrogen and the other is CH; T is oxygen or sulfur; and Z is an optionally substituted phenyl group or an optionally substituted heterocylyl group.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: August 17, 2004
    Assignee: Syngenta Limited
    Inventors: John Martin Clough, Christopher Richard Ayles Godfrey, Ian Thomas Streeting, Rex Cheetham, Paul John de Fraine, David Bartholomew, James John Eshelby
  • Publication number: 20040092746
    Abstract: The invention provides fungicidal compounds of formula (I) or stereoisomers thereof: 1
    Type: Application
    Filed: June 27, 2003
    Publication date: May 13, 2004
    Inventors: John Martin Clough, Christopher Richard Ayles Godfrey, Ian Thomas Streeting, Rex Cheetham, Paul John de Fraine, David Bartholomew, James John Eshelby
  • Patent number: 6670362
    Abstract: Compounds of formula (I), pharmaceutical formulations thereof and the use of such compounds for treating endothelin mediated diseases or conditions are described herein. The compounds of the present invention have affinity for endothelin receptors, are selective for ETA over ETB, and thus are useful in the treatment of conditions mediated by endothelin.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: December 30, 2003
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Anthony Logan Chubb, Douglas James Critcher, James John Eshelby, Darren John Schulz
  • Publication number: 20030232848
    Abstract: Compounds of formulae (IA) and (IB): 1
    Type: Application
    Filed: April 2, 2003
    Publication date: December 18, 2003
    Applicant: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan, James John Eshelby, Darren John Schulz
  • Patent number: 6613773
    Abstract: The invention provides fungicidal compounds of formula (I) or stereoisomers thereof: wherein X is CH2O; A is hydrogen; E is hydrogen; q is 1; any two of K, L and M are nitrogen and the other is CH; T is oxygen or sulfur; and Z is an optionally substituted phenyl group or an optionally substituted heterocyclyl group.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: September 2, 2003
    Assignee: Syngenta Limited
    Inventors: John Martin Clough, Christopher Richard Ayles Godfrey, Ian Thomas Streeting, Rex Cheetham, Paul John de Fraine, David Bartholomew, James John Eshelby
  • Patent number: 6573270
    Abstract: Compounds of formulae (IA) and (IB): wherein R1, R2, R3, Ar1 and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: June 3, 2003
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Darren John Schulz
  • Publication number: 20030060626
    Abstract: The invention provides fungicidal compounds of formula (I) or stereoisomers thereof: 1
    Type: Application
    Filed: March 5, 2002
    Publication date: March 27, 2003
    Inventors: John Martin Clough, Christopher Richard Ayles Godfrey, Ian Thomas Streeting, Rex Cheetham, Paul John de Fraine, David Bartholomew, James John Eshelby
  • Publication number: 20020061889
    Abstract: Compounds of formula (I), pharmaceutical formulations thereof and the use of such compounds for treating endothelin mediated diseases or conditions are described herein.
    Type: Application
    Filed: September 12, 2001
    Publication date: May 23, 2002
    Inventors: Bernard Joseph Banks, Anthony Logan Chubb, Douglas James Critcher, James John Eshelby, Darren John Schulz
  • Patent number: 6387915
    Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein. Such compounds are useful in the treatment of conditions mediated by endothelin, in particular, conditions mediated by endothelin ETA.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz
  • Publication number: 20020019408
    Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein.
    Type: Application
    Filed: May 30, 2001
    Publication date: February 14, 2002
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz